HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NTRB
Nutriband Inc.
There isn't enough reported data to score NTRB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NTRB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
NTRB's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NTRB PE Valuation
NTRB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NTRB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect NTRB's losses to shrink, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
NTRB has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus NTRB down 170%.
NTRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.90 | -$0.13 |
| Q1 2025 | -$0.99 | -$0.30 |
| Q4 2024 | -$0.71 | -$0.07 |
| Q3 2024 | -$0.81 | -$0.25 |
| Q2 2022 | -$0.84 | -$0.43 |
| Q1 2022 | -$0.80 | -$0.36 |
| Q4 2021 | -$0.67 | -$0.42 |
| Q3 2021 | -$0.45 | -$0.09 |
NTRB lost $0.57 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NTRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NTRB on profitability, with a higher operating margin.
NTRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $437.5K | -30% |
| Q2 2026 | $433.4K | -35% |
| Q1 2026 | $400.7K | -38% |
| Q4 2025 | $346.1K | -46% |
| Q3 2025 | $622.5K | +41% |
| Q2 2025 | $667.4K | +63% |
| Q1 2025 | $642.4K | +22% |
| Q4 2024 | $645.8K | +51% |
NTRB's revenue has slid since its 2025 peak: $437,514 last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -204% | +118 points |
| Q2 2026 | -289% | -78 points |
| Q1 2026 | -255% | +611 points |
| Q4 2025 | -1121% | -900 points |
| Q3 2025 | -322% | -3.5 points |
| Q2 2025 | -212% | +251 points |
| Q1 2025 | -865% | -616 points |
| Q4 2024 | -221% | +182 points |
NTRB's operating margin was −204% last quarter, up 118 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NTRB has the stronger cash trend. Its trailing FCF is down 71% versus its history, compared with HIMS at down 84%.
NTRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$731.8K | +$507.4K |
| Q4 2025 | -$1.8M | -$695.9K |
| Q3 2025 | -$1.3M | +$269.3K |
| Q2 2025 | -$1.3M | -$502.2K |
| Q1 2025 | -$1.2M | -$471.9K |
| Q4 2024 | -$1.1M | +$7.7K |
| Q3 2024 | -$1.6M | -$587.5K |
| Q2 2024 | -$840.1K | -$87.6K |
NTRB has burned cash in almost every quarter: −$5M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NTRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NTRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +9.3% | +1M shares |
| 3 years | +44% | +3.7M shares |
| 5 years | +84% | +5.6M shares |
| Available history | +92% | +5.8M shares |
NTRB has 12M diluted shares, up 9.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NTRB Net Leverage
NTRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NTRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 48.5 | Neutral |
NTRB's weekly RSI is 55 (neutral) and its Stochastic is 48 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NTRB PE vs Healthcare Sector
NTRB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NTRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.47 | 7.7% below |
| 20 week MA | $5.16 | 16% above |
| 50 week MA | $4.51 | 32% above |
| 100 week MA | $5.54 | 7.8% above |
| 200 week MA | $4.69 | 27% above |
NTRB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NTRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $5.74 | $3.10 | -46% |
| 2022 | $3.10 | $3.59 | +16% |
| 2023 | $3.59 | $2.32 | -35% |
| 2024 | $2.32 | $3.85 | +66% |
| 2025 | $3.85 | $4.80 | +25% |
| 2026 YTD | $4.80 | $5.97 | +24% |
NTRB has the edge over HIMS on returns for 2026, with the stronger performance.